Justin Rosenau, MD
Family Medicine · Jamestown, NDNPI 1275973091
Payments from drug & device makers
Across 64 payments — averaging $13.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$103
- Novo Nordisk$82
- AstraZeneca$65
- Dexcom, Inc.$61
- Johnson & Johnson$61
- Boehringer Ingelheim$57
- plus $466 from 20 others
What the payments were for
- Food & beverage$896100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $103 |
| Novo Nordisk | 6 | $82 |
| AstraZeneca | 5 | $65 |
| Dexcom, Inc. | 4 | $61 |
| Johnson & Johnson | 3 | $61 |
| Boehringer Ingelheim | 4 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41 |
| Lilly USA, LLC | 3 | $35 |
| GSK | 2 | $35 |
| Pfizer | 3 | $34 |
| Novartis | 2 | $29 |
| Mylan Specialty L.p. | 2 | $29 |
| Organon | 4 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Merck | 2 | $26 |
| Biogen | 2 | $24 |
| Boston Scientific | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Mimedx Group, Inc. | 1 | $15 |
| Dermira, Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $11 |
How this compares
$896 in reported general payments places this provider in the 80th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 198 | $142,470 |
| JardianceEmpagliflozin | 126 | $105,115 |
| OzempicSemaglutide | 82 | $82,776 |
| Dupixent PenDupilumab | 13 | $49,857 |
| XareltoRivaroxaban | 50 | $47,103 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $26,319 |
| FarxigaDapagliflozin Propanediol | 30 | $20,750 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $19,298 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $17,692 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $16,317 |
| TrulicityDulaglutide | 15 | $14,053 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $13,581 |
| EntrestoSacubitril/Valsartan | 16 | $9,984 |
| BrilintaTicagrelor | 30 | $9,671 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $8,474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $34 | $142,470198 claims |
| Boehringer IngelheimJardiance, Tradjenta | $57 | $112,170143 claims |
| Novo NordiskOzempic | $82 | $82,77682 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $35 | $50,23999 claims |
| Johnson & JohnsonXarelto | $61 | $47,10350 claims |
| AstraZenecaFarxiga, Brilinta | $65 | $30,42160 claims |
| Lilly USA, LLCTrulicity | $35 | $14,05315 claims |
| NovartisEntresto | $29 | $9,98416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Jamestown
- Derek BricknerJamestown$2K
- Stacy Roers IrmenJamestown$1K
- William McMillanJamestown$1K
- Swarna YadlapalliFargo$2.9M
- Joel SchockFargo$1.2M
- Hoadley HarrisFargo$830K
- Richard VetterWest Fargo$294K
- Thomas ThorsonMandan$241K
- Gregory GreekGrand Forks$216K
- Katherine NeubauerWest Fargo$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.